Ultravate Lotion
NDC Package 73159-008-60

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Ultravate (halobetasol propionate) lotions is a medication used to treat a variety of skin conditions (such as eczema, dermatitis, psoriasis, rash). This formulation utilizes a lotion delivery system. Marketed by Lacer Pharma, Llc, this product is identified by NDC 73159-008 and is authorized under FDA application NDA208183.

Identification & Billing

NDC Package Code
73159-008-60
Package Description
1 BOTTLE in 1 CARTON / 59 g in 1 BOTTLE
Product Code
73159-008
11-Digit Billing Format
73159000860
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ultravate
Non-Proprietary Name
Halobetasol Propionate
Substance Name
Halobetasol Propionate
Dosage Form
Lotion - An emulsion, liquid1 dosage form. This dosage form is generally for external application to the skin.2
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
HALOBETASOL PROPIONATE .5 mg/g
Pharmacologic Class
Usage Information
This medication is used to treat a variety of skin conditions (such as eczema, dermatitis, psoriasis, rash). Halobetasol reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a very strong (super-high potency) corticosteroid.

Regulatory & Marketing

Labeler Name
Lacer Pharma, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA208183
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-06-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73159-008-60 identifies a specific commercial package of 1 bottle in 1 carton / 59 g in 1 bottle of Ultravate, a human prescription drug labeled by Lacer Pharma, Llc. This lotion is formulated for topical use and contains halobetasol propionate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lacer Pharma, Llc on April 06, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat a variety of skin conditions (such as eczema, dermatitis, psoriasis, rash). Halobetasol reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a very strong (super-high potency) corticosteroid.

How is this Lacer Pharma, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73159000860. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73159-008-60
11-Digit CMS (5-4-2)
73159-0008-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.